Experimental studies have provided evidence that the visual processing areas of the primate brain represent facial identity and facial expression within different subpopulations of neurons. For example, in non-human primates there is evidence that cells within the inferior temporal gyrus (TE) respond primarily to facial identity, while cells within the superior temporal sulcus (STS) respond to facial expression. More recently, it has been found that the orbitofrontal cortex (OFC) of non-human primates contains some cells that respond exclusively to changes in facial identity, while other cells respond exclusively to facial expression. How might the primate visual system develop physically separate representations of facial identity and expression given that the visual system is always exposed to simultaneous combinations of facial identity and expression during learning? In this paper, a biologically plausible neural network model, VisNet, of the ventral visual pathway is trained on a set of carefully-designed cartoon faces with different identities and expressions. The VisNet model architecture is composed of a hierarchical series of four Self-Organising Maps (SOMs), with associative learning in the feedforward synaptic connections between successive layers. During learning, the network develops separate clusters of cells that respond exclusively to either facial identity or facial expression. We interpret the performance of the network in terms of the learning properties of SOMs, which are able to exploit the statistical indendependence between facial identity and expression.

The model of p Ising spins coupled to 2d gravity, in the form of a sum over planar φ 3 graphs, is studied and in particular the two-point and spin-spin correlation functions are considered. We first solve a toy model in which only a partial summation over spin configurations is performed and, using a modified geodesic distance, various correlation functions are determined. The two-point function has a diverging length scale associated with it. The critical exponents are calculated and it is shown that all the standard scaling relations apply. Next the full model is studied, in which all spin configurations are included. Many of the considerations for the toy model apply for the full model, which also has a diverging geometric correlation length associated with the transition to a branched polymer phase. Using a transfer function we show that the two-point and spin-spin correlation functions decay exponentially with distance. Finally, by assuming various scaling relations, we make a prediction for the critical exponents at the transition between the magnetized and branched polymer phases in the full model.

We study a model in which p independent Ising spins are coupled to 2d quantum gravity (in the form of dynamical planar φ 3 graphs). Consideration is given to the p → ∞ limit in which the partition function becomes dominated by certain graphs; we identify most of these graphs. A truncated model is solved exactly providing information about the behaviour of the full model in the limit β → 0. Finally, we derive a bound for the critical value of the coupling constant, βc and examine the magnetization transition in the limit p → 0.

We discuss how concepts such as geodesic length and the volume of space-time can appear in 2d topological gravity. We then construct a detailed mapping between the reduced Hermitian matrix model and 2d topological gravity at genus zero. This leads to a complete solution of the counting problem for planar graphs with vertices of even coordination number. The connection between multi-critical matrix models and multi-critical topological gravity at genus zero is studied in some detail.

Nilutamide is a nonsteroidal antiandrogen with affinity for androgen receptors but not for progestogen, estrogen, or glucocorticoid receptors. Consequently, nilutamide blocks the action of androgens of adrenal and testicular origin which stimulate the growth of normal and cancerous prostatic tissue. Nilutamide has a long half-life which permits once-daily administration. Nilutamide is usually given in combination with surgical or chemical castration using gonadotrophin-releasing hormone (GnRH) [luteinising hormone-releasing hormone (LHRH)] agonists. In castrated patients the addition of nilutamide improves objective response rates, bone pain, urinary symptoms, tumour markers and time to disease progression. The tolerance of nilutamide is generally acceptable. Adverse effects are usually mild and reversible and consistent with androgen depletion. Unexpected but reversible adverse effects of nilutamide include delayed adaption to dark after exposure to bright light, transient increases in transaminases, and more severe but rare interstitial pneumonitis. Thus, nilutamide is a welcome treatment option that may be particularly useful in patients to whom the convenience of once-daily administration is seen as a worthwhile benefit.